BANK VONTOBEL/CALL/ELI LILLY & CO/780/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 18:55:05 25/06/2024 BST | ||
| 13.51 EUR | +3.45% |
|
| Current month | +82.08% | ||
| 1 month | +88.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 13.51 | +3.45% |
| 24/06/24 | 13.06 | +7.49% |
| 21/06/24 | 12.15 | +6.30% |
| 20/06/24 | 11.43 | -10.42% |
| 19/06/24 | 12.76 | +5.19% |
Delayed Quote Deutsche Boerse AG
Last update June 25, 2024 at 06:55 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM9ZDT |
| ISIN | DE000VM9ZDT0 |
| Date issued | 07/02/2024 |
| Strike | 780 $ |
| Maturity | 20/09/2024 (87 Days) |
| Parity | 10 : 1 |
| Emission price | 3.95 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.51 € |
|---|---|
| Lowest since issue | 3.79 € |
| Spread | 0.02 € |
| Spread % | 0.15% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Warrants
- Warrant
